サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1798913

ヒトリコンビナントインスリンの世界市場

Human Recombinant Insulin

出版日
ページ情報
英文 189 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
ヒトリコンビナントインスリンの世界市場
出版日: 2025年08月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 189 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ヒトリコンビナントインスリンの世界市場は2030年までに310億米ドルに達する見込み

2024年に276億米ドルと推定されるヒトリコンビナントインスリンの世界市場は、分析期間2024-2030年にCAGR 1.9%で成長し、2030年には310億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである短時間作用型ヒトインスリンは、CAGR 1.5%を記録し、分析期間終了時には176億米ドルに達すると予測されます。中間作用型ヒトインスリン・セグメントの成長率は、分析期間中CAGR 2.7%と推定されます。

米国市場は75億米ドルと推定、中国はCAGR 3.6%で成長すると予測

米国のヒトリコンビナントインスリン市場は、2024年に75億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに57億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは3.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.8%と1.6%と予測されています。欧州では、ドイツがCAGR 1.1%で成長すると予測されています。

世界のヒトリコンビナントインスリン市場- 主要動向と促進要因まとめ

なぜ遺伝子組換えインスリンが今日の糖尿病管理の中心なのか？

ヒトリコンビナントインスリンは、その一貫性、免疫原性の低減、スケーラブルな生産により、糖尿病管理の主要治療となっています。リコンビナントDNA技術を使用して製造されたこのインスリンは、動物由来の旧タイプのインスリンに取って代わり、ヒトの生理機能との適合性を向上させています。1型および2型糖尿病患者は血糖値を調節するためにインスリンを必要とするため、遺伝子組換え製剤は疾患のコントロールと合併症の予防に不可欠です。ベーサルボルスレジメンとフレキシブルな投与法の普及により、速効型および長時間作用型の遺伝子組換えインスリンアナログ製剤への依存度がさらに高まっています。

世界の糖尿病有病率の上昇により、予測可能な薬物動態と副作用の低減を実現するインスリン製剤への需要が高まっています。ヒトリコンビナントインスリンは、病院での急性期治療から長期にわたる外来使用まで、患者集団や治療環境全体にわたって信頼性の高いソリューションを提供します。アナログ製剤とヒト型バイオシミラー製剤の両方の開発により、高所得国市場と新興国市場の両方において利用しやすくなっています。糖糖尿病治療の認識が向上し、早期診断率が上昇するにつれて、インスリン療法に対する患者の遵守率は向上し続け、製品の普及がさらに進みます。

製剤革新とデリバリー技術はどのように進歩しているか？

製剤の改良により、遺伝子組換えインスリン製剤の治療プロファイルと使用性が向上しています。長時間作用型製剤は現在、1日1回、あるいは週1回使用できるように設計されており、コンプライアンスの向上と注射回数の減少に役立っています。速効型インスリン製剤は、より早く作用が発現し、より短い作用時間で、より優れた食後血糖コントロールを実現するよう改良されています。これらのオプションにより、患者はライフスタイル、食事、活動レベルに応じてレジメンをカスタマイズすることができます。バイオシミラーもまた、有効性や安全性を損なうことなく、先発品のインスリン製剤に代わる安価な代替品を提供し、人気を集めています。

製剤の変化と並行して、デリバリーシステムも進化しています。多くの地域で、プレフィルドインスリンペン、カートリッジシステム、再利用可能なデバイスが、従来のバイアルやシリンジに取って代わっています。デジタル投与追跡とBluetooth接続を備えたスマートインスリンペンは、統合糖尿病管理プラットフォームの一部になりつつあります。これらのシステムは、ユーザーがインスリンの使用量を追跡し、投与漏れや重複投与を避けるのを助けることによって、より良いグルコースコントロールを可能にします。連続グルコースモニタリング装置と互換性のあるインスリンポンプも進歩しており、一部の患者グループにおいては、クローズドループシステムにより、ほぼ自動化されたインスリン投与が可能となっています。

ヒトリコンビナントインスリンの需要が最も急増しているのはどこですか？

ヒトリコンビナントインスリンの需要が最も伸びているのは、都市化、食生活の変化、座りがちなライフスタイルにより糖尿病有病率が上昇している新興市場です。アジア太平洋、ラテンアメリカ、中東の国々では、公衆衛生プログラム、バイオシミラー医薬品メーカーとの提携、必須医薬品リストへのインスリン製剤の追加などにより、インスリン製剤へのアクセスが拡大しています。啓発キャンペーンやスクリーニングの取り組みによって診断が改善され、長期インスリン療法を受ける患者層が拡大しています。

新興国市場では、人口の高齢化とインスリンを必要とする2型糖尿病の増加が需要を支えています。医療制度は価値に基づく医療へとシフトしており、より良いアドヒアランスとアウトカムをサポートするバイオシミラーとデジタルデリバリーシステムの採用を奨励しています。病院、診療所、在宅医療プロバイダーからのヘルスケア需要も、特に高齢者集団の合併症管理に対応して増加しています。政府および民間支払機関は、インスリンの手頃な価格と入手可能性を確保するため、価格交渉や流通モデルにおいて積極的な役割を果たしています。

ヒトリコンビナントインスリン市場の成長の原動力は？

ヒトリコンビナントインスリン市場の成長は、世界の糖尿病罹患率の上昇、インスリン製剤技術の向上、先進デリバリーシステムの採用増加など、いくつかの要因によってもたらされます。アナログ設計の技術的進歩は、長時間作用型、超速効型、低変量型インスリン製剤の開発を支えています。これらの技術革新は、治療精度と患者の快適性を向上させるとともに、より優れた血糖コントロールを可能にします。デジタルペン、ウェアラブルポンプ、モバイル連動追跡ツールは、特に若年層や技術リテラシーの高い患者集団において、インスリン投与とアドヒアランスを向上させています。

公衆衛生プログラム、施設プロバイダー、在宅医療における最終用途の拡大により、需要の一貫性が高まっています。新興市場では、現地生産を強化し、バイオシミラー医薬品の普及を促進する取り組みにより、サプライチェーンの安定性と価格が向上しています。製薬企業とヘルスケアシステムとのパートナーシップにより、農村部や十分なサービスを受けていない地域でも幅広い流通が可能になっています。高所得国では、価値観に基づく治療と統合された糖尿病治療プラットフォームへのシフトが、インスリンの長期使用を強化しています。これらの開発により、医療の革新、投与の効率、患者のアクセスが調整され、ヒトリコンビナントインスリン市場の持続的な成長が促進されます。

セグメント

医薬品（短時間作用型ヒトインスリン製剤、中間作用型ヒトインスリン製剤、プレミックス型ヒトインスリン製剤）

調査対象企業の例

  • Adocia
  • Aspen Pharmacare
  • Biocon Ltd
  • Biopharmax
  • Bioton S.A.
  • Civica Rx
  • Dongfeng Biologics
  • Gan & Lee Pharmaceuticals, Ltd.
  • Hanmi Pharm
  • Julphar Gulf Pharmaceutical Industries
  • MannKind Corporation
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals
  • Sandoz（Novartis）
  • Sanofi S.A.
  • Tonghua Dongbao Pharmaceutical
  • Wanbang Biopharmaceuticals Co., Ltd.
  • Wockhardt Ltd
  • Ypsomed AG
  • Zhuhai United Laboratories Co., Ltd.

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38925

Global Human Recombinant Insulin Market to Reach US$31.0 Billion by 2030

The global market for Human Recombinant Insulin estimated at US$27.6 Billion in the year 2024, is expected to reach US$31.0 Billion by 2030, growing at a CAGR of 1.9% over the analysis period 2024-2030. Short-acting Human Insulin, one of the segments analyzed in the report, is expected to record a 1.5% CAGR and reach US$17.6 Billion by the end of the analysis period. Growth in the Intermediate-acting Human Insulin segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.5 Billion While China is Forecast to Grow at 3.6% CAGR

The Human Recombinant Insulin market in the U.S. is estimated at US$7.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.7 Billion by the year 2030 trailing a CAGR of 3.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.

Global Human Recombinant Insulin Market - Key Trends & Drivers Summarized

Why Is Recombinant Insulin Central to Diabetes Management Today?

Human recombinant insulin has become the primary treatment for diabetes management due to its consistency, reduced immunogenicity, and scalable production. Derived using recombinant DNA technology, it replaces older forms of animal-derived insulin, offering improved compatibility with human physiology. Patients with type 1 and type 2 diabetes require insulin to regulate blood glucose levels, making recombinant formulations critical for disease control and prevention of complications. The widespread adoption of basal-bolus regimens and flexible dosing has further increased reliance on rapid-acting and long-acting recombinant insulin analogs.

Rising diabetes prevalence globally has increased demand for insulin products that provide predictable pharmacokinetics and reduced adverse reactions. Human recombinant insulin offers a reliable solution across patient populations and care settings, from hospital-based acute care to long-term outpatient use. Availability of both analog and human biosimilar variants has supported accessibility in both high-income and developing markets. As awareness of diabetes care improves and early diagnosis rates increase, patient adherence to insulin therapy continues to rise, further boosting product uptake.

How Are Formulation Innovations and Delivery Technologies Advancing?

Formulation improvements are enhancing the therapeutic profile and usability of recombinant insulin products. Long-acting formulations are now designed for once-daily or even weekly use, helping improve compliance and reduce injection frequency. Rapid-acting analogs are being refined to deliver better post-meal glucose control with faster onset and shorter duration of action. These options allow patients to personalize regimens based on lifestyle, diet, and activity level. Biosimilars are also gaining traction, offering lower-cost alternatives to branded insulins without compromising efficacy or safety.

Delivery systems are evolving in parallel with formulation changes. Prefilled insulin pens, cartridge systems, and reusable devices have replaced traditional vials and syringes in many regions. Smart insulin pens with digital dose tracking and Bluetooth connectivity are becoming part of integrated diabetes management platforms. These systems enable better glucose control by helping users track insulin usage and avoid missed or duplicate doses. Insulin pumps compatible with continuous glucose monitoring devices are also advancing, with closed-loop systems providing near-automated insulin delivery in select patient groups.

Where Is Demand for Human Recombinant Insulin Rising Most Rapidly?

Demand for human recombinant insulin is growing fastest in emerging markets where diabetes prevalence is rising due to urbanization, dietary changes, and sedentary lifestyles. Countries in Asia Pacific, Latin America, and the Middle East are scaling up insulin access through public health programs, partnerships with biosimilar manufacturers, and increased inclusion of insulin in essential medicine lists. Awareness campaigns and screening initiatives are improving diagnosis and expanding the patient base for long-term insulin therapy.

In developed markets, aging populations and increasing incidence of insulin-requiring type 2 diabetes are sustaining demand. Health systems are shifting towards value-based care, encouraging adoption of biosimilars and digital delivery systems that support better adherence and outcomes. Institutional demand from hospitals, clinics, and home healthcare providers is also rising, particularly in response to comorbidity management in elderly populations. Government and private payers are playing an active role in price negotiations and distribution models to ensure insulin affordability and availability.

What Is Driving Growth in the Human Recombinant Insulin Market?

Growth in the human recombinant insulin market is driven by several factors including rising global diabetes incidence, improvements in insulin formulation technologies, and increased adoption of advanced delivery systems. Technological advancements in analog design are supporting the development of long-acting, ultra-fast, and low-variability insulin products. These innovations improve treatment precision and patient comfort while enabling better glycemic control. Digital pens, wearable pumps, and mobile-linked tracking tools are enhancing insulin delivery and adherence, particularly in younger and tech-literate patient populations.

End-use expansion across public health programs, institutional providers, and home-based care is increasing demand consistency. In emerging markets, efforts to strengthen local manufacturing and promote biosimilar uptake are improving supply chain stability and affordability. Partnerships between pharmaceutical companies and healthcare systems are enabling broad distribution, even in rural or underserved regions. In high-income countries, the shift towards value-based treatment and integrated diabetes care platforms is reinforcing long-term insulin use. Together, these developments are driving sustainable growth in the human recombinant insulin market by aligning medical innovation, delivery efficiency, and patient access.

SCOPE OF STUDY:

The report analyzes the Human Recombinant Insulin market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug (Short-acting Human Insulin, Intermediate-acting Human Insulin, Premixed Human Insulin)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Adocia
  • Aspen Pharmacare
  • Biocon Ltd
  • Biopharmax
  • Bioton S.A.
  • Civica Rx
  • Dongfeng Biologics
  • Gan & Lee Pharmaceuticals, Ltd.
  • Hanmi Pharm
  • Julphar Gulf Pharmaceutical Industries
  • MannKind Corporation
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals
  • Sandoz (Novartis)
  • Sanofi S.A.
  • Tonghua Dongbao Pharmaceutical
  • Wanbang Biopharmaceuticals Co., Ltd.
  • Wockhardt Ltd
  • Ypsomed AG
  • Zhuhai United Laboratories Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Human Recombinant Insulin - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Diabetes Worldwide Drives Sustained Demand for Safe and Effective Human Recombinant Insulin Therapies
    • Global Shift Toward Biosynthetic Insulin Use Over Animal-Sourced Products Strengthens Business Case for Recombinant Insulin Formulations
    • Increasing Access to Insulin Therapy in Developing Economies Spurs Demand for Cost-Effective Recombinant Insulin Solutions
    • OEM Focus on Improved Pharmacokinetics and Purity Profiles Enhances Clinical Preference for Recombinant Insulin Products
    • Growth in Type 1 and Type 2 Diabetes Patient Base Throws Spotlight on Basal and Rapid-Acting Recombinant Insulin Regimens
    • Regulatory Approvals of Follow-On Biologics and Biosimilars Expand Competitive Access to Affordable Insulin Therapies
    • Expansion of Public Health Programs and Government Insulin Procurement Initiatives Fuels Market Penetration in Low-Income Regions
    • Rising Adoption of Insulin Pens and Smart Delivery Devices Supports Use of Recombinant Insulin in User-Friendly Formats
    • OEM Innovation in Long-Acting and Ultra-Fast Insulin Molecules Enhances Convenience and Glycemic Control
    • Growing Emphasis on Cold Chain Logistics and Storage Efficiency Improves Access to Recombinant Insulin in Remote Areas
    • Increased Private and Public Insurance Coverage Strengthens Patient Access to Recombinant Insulin Therapie
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Human Recombinant Insulin Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Human Recombinant Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Human Recombinant Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Human Recombinant Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Short-acting Human Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Short-acting Human Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Short-acting Human Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Intermediate-acting Human Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Intermediate-acting Human Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Intermediate-acting Human Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Premixed Human Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Premixed Human Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Premixed Human Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Human Recombinant Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • JAPAN
    • Human Recombinant Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • CHINA
    • Human Recombinant Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: China 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • EUROPE
    • Human Recombinant Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Human Recombinant Insulin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Human Recombinant Insulin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Human Recombinant Insulin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • FRANCE
    • Human Recombinant Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: France 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • GERMANY
    • Human Recombinant Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Human Recombinant Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Human Recombinant Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Human Recombinant Insulin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Human Recombinant Insulin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Human Recombinant Insulin by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Human Recombinant Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • INDIA
    • Human Recombinant Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: India 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Human Recombinant Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Human Recombinant Insulin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Human Recombinant Insulin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Human Recombinant Insulin by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Human Recombinant Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Human Recombinant Insulin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Human Recombinant Insulin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Human Recombinant Insulin by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030
  • AFRICA
    • Human Recombinant Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Human Recombinant Insulin by Drug - Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Human Recombinant Insulin by Drug - Percentage Breakdown of Value Sales for Short-acting Human Insulin, Intermediate-acting Human Insulin and Premixed Human Insulin for the Years 2014, 2025 & 2030

IV. COMPETITION